Foghorn Therapeutics Inc. (FHTX) revenue
Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.91M in fiscal 2025 (the year ended December 31, 2025). That is 36.8% higher than the $22.60M of fiscal 2024. Figures as of 18 Nov 2026, 12:48 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- $30.91M
- Change on fiscal 2024
- +36.8%
- Growth, 5 years
- +135.1% a year
- Highest on record
- $34.16Mfiscal 2023
- Lowest on record
- $430.00Kfiscal 2020
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Foghorn Therapeutics Inc. revenue, in more detail
Over the five fiscal years to 2025 revenue grew at a compound 135.1% a year. Across the 6 fiscal years on record (2020–2025), the highest was $34.16M in fiscal 2023 and the lowest $430.00K in fiscal 2020.
Revenue by fiscal year
Foghorn Therapeutics Inc. revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | $30.91M | 36.8% up | |
| 2024 | $22.60M | 33.8% down | |
| 2023 | $34.16M | 77.6% up | |
| 2022 | $19.23M | 1,357.8% up | |
| 2021 | $1.32M | 206.7% up | |
| 2020 | $430.00K | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Foghorn Therapeutics Inc., figure by figure
- Foghorn Therapeutics Inc. market cap
- Foghorn Therapeutics Inc. earnings
- Foghorn Therapeutics Inc. earnings per share (EPS)
- Foghorn Therapeutics Inc. P/E ratio
- Foghorn Therapeutics Inc. P/S ratio
- Foghorn Therapeutics Inc. P/B ratio
- Foghorn Therapeutics Inc. free cash flow
- Foghorn Therapeutics Inc. operating margin
- Foghorn Therapeutics Inc. dividend
- Foghorn Therapeutics Inc. shares outstanding
- Foghorn Therapeutics Inc. total debt
- Foghorn Therapeutics Inc. cash on hand
- Foghorn Therapeutics Inc. total assets
- Foghorn Therapeutics Inc. return on equity (ROE)
- Foghorn Therapeutics Inc. return on invested capital (ROIC)
Foghorn Therapeutics Inc. (FHTX) overview: price, valuation and scorecard
Foghorn Therapeutics Inc. revenue: questions and answers
What is Foghorn Therapeutics Inc.'s revenue?
Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.91M in fiscal 2025 (the year ended December 31, 2025). That is 36.8% higher than the $22.60M of fiscal 2024.
What is the growth rate of Foghorn Therapeutics Inc.'s revenue?
Over the five fiscal years to 2025 revenue grew at a compound 135.1% a year.
What are the highest and lowest revenue figures on record for Foghorn Therapeutics Inc.?
Across the 6 fiscal years on record (2020–2025), the highest was $34.16M in fiscal 2023 and the lowest $430.00K in fiscal 2020.
How is Foghorn Therapeutics Inc.'s revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Foghorn Therapeutics Inc. it is on record here for 6 fiscal years, 2020 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Foghorn Therapeutics Inc. (FHTX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/FHTX/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.